A large-scale clinical study of 1,700 patients showed ubrogepant to be effective at...
Ubrogepant is shown to effectively treat migraine symptoms
A large-scale clinical study of 1,700 patients showed ubrogepant to be effective at easing pain and light or sound sensitivity as well as providing nausea relief.
Libella to study gene therapy to reverse ageing in Colombia
Libella Gene Therapeutics has received approval from an institutional review board (IRB) to conduct a clinical trial in Colombia of a gene therapy intended to treat and reverse ageing.
Evolution Research and Invicro to offer clinical research services
Evolution Research Group (ERG) and Konica Minolta’s Invicro have collaborated to provide early-to-late-phase clinical research services for biotech and pharma sponsors.
Therapix’s THX-110 shows positive results in OSA patients
Therapix Biosciences has announced that investigational drug THX-110 yielded favourable data in a Phase IIa clinical trial involving adults with obstructive sleep apnea (OSA).
2018 was a top year for clinical trials for depression
Looking at depression clinical trials in the database with a start date from 2015 to present, 2018 had the most clinical trials.
Novartis-Incyte’s Jakavi yields positive data in GvHD trial
Novartis and Incyte have reported positive results from the Phase III REACH2 clinical trial of Jakavi (ruxolitinib) conducted in steroid-refractory acute graft-versus-host disease (GvHD) patients.
Promising results for use of catabolic enzyme inhibitors in treatment of PTSD
The US National Institute on Alcohol Abuse’s AM-3506 and Sanofi’s SAR-411298 are both at the preclinical stage of development for PTSD.
Trends in clinical trials for gene therapies in neurology
84% of gene therapy trials happening in various neurology indications, listed in GlobalData’s Pharma Intelligence Center, are in early-stage development, that is Phase I, Phase I/II, and Phase II.
Psilocybin depression therapy faces cost-effectiveness challenges versus J&J’s Spravato
Companies researching psilocybin therapy have ongoing Phase II or III clinical trials, but will need to optimise the treatment paradigm to streamline costs, experts said.
Trial halted early as Nuplazid shows strong efficacy in dementia-related psychosis
Nuplazid is being investigated for the treatment of delusions and hallucinations associated with dementia-related psychosis (DRP).